Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding

Lausanne-based Alithea Genomics has announced the successful closing of a CHF 2.8 million extension of its seed financing, a significant step towards revolutionizing RNA sequencing technologies.

Alithea Genomics, renowned for its trailblazing Bulk RNA Barcoding and sequencing (BRB-seq) technology, sets its sights on a series of ambitious endeavors including the launch of new RNA sequencing products, amplification of production capacity, development of pioneering technologies, and the establishment of a United States subsidiary.

The company’s BRB-seq technology represents a paradigm shift in RNA sequencing, offering an ultra-high throughput and cost-effective alternative to traditional methods. This innovative approach simplifies the sample preparation process, enabling the processing of hundreds of RNA samples simultaneously, thereby accelerating research and drug discovery ventures.

New headquarters in the heart of the Health Valley

Spearheaded by Novalis Biotech and joined by new investor TechU Ventures, alongside existing stakeholders, the new funding in the amount of CHF 2.8 million will catalyze Alithea’s commercial trajectory, with plans to broaden the reach of its groundbreaking BRB-seq and DRUG-seq technologies. DRUG-seq, an addition to Alithea’s portfolio, eliminates the need for RNA isolation, offering a streamlined path for drug development processes, and has already garnered attention from major pharmaceutical entities.

With the establishment of a subsidiary in the United States, Alithea aims to tap into the lucrative American market, fostering international collaborations and extending its innovative solutions to a wider audience. Furthermore, the move to new headquarters in Lausanne, equipped with state-of-the-art laboratories, reinforces Alithea’s commitment to advancing RNA sequencing.